IFLScience on MSN1d
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical Trials
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
Novel inhalable gene therapy trialed for people with cystic fibrosis
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
GlobalData on MSN2d
Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
pharmaphorum1d
Trial of Boehringer's cystic fibrosis gene therapy imminent
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
technologynetworks2d
Inhalable Gene Therapy Trial Begins for Cystic Fibrosis Patients
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...
Armed robbery in Revesby2d
Inhalable Gene Therapy Trialled for Cystic Fibrosis
Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...
News Medical3d
Inhalable gene therapy tested for cystic fibrosis treatment in the UK and Europe
Cystic fibrosis (CF) is caused by defects in the ... The new lentiviral vector-based gene therapy works by inserting a functioning copy of the CFTR gene in the DNA of the epithelial cells in ...
Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
Yahoo Finance2d
Boehringer and partners commence gene therapy trial for cystic fibrosis
"Boehringer and partners commence gene therapy trial for cystic fibrosis" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Yahoo Finance3d
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway ...